Replacement of the native CARM1 with its catalytically dead mutant or with an Arg-to-Lys point mutation at the Arg1064 methylation site of BAF155 is sufficient to abolish the invasive capability of breast cancer cells (Wang et al., 2014a). This evidence concerns the gene CARM1 and breast carcinoma.